Yüklüyor......

Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial

PURPOSE: Docetaxel and abiraterone acetate plus prednisone or prednisolone (AAP) both improve survival when commenced alongside standard of care (SOC) androgen deprivation therapy in locally advanced or metastatic hormone-sensitive prostate cancer. Thus, patient-reported quality of life (QOL) data m...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Oncol
Asıl Yazarlar: Rush, Hannah L., Murphy, Laura, Morgans, Alicia K., Clarke, Noel W., Cook, Adrian D., Attard, Gerhardt, Macnair, Archie, Dearnaley, David P., Parker, Christopher C., Russell, J. Martin, Gillessen, Silke, Matheson, David, Millman, Robin, Brawley, Christopher D., Pugh, Cheryl, Tanguay, Jacob S., Jones, Robert J., Wagstaff, John, Rudman, Sarah, O'Sullivan, Joe M., Gale, Joanna, Birtle, Alison, Protheroe, Andrew, Gray, Emma, Perna, Carla, Tolan, Shaun, McPhail, Neil, Malik, Zaf I., Vengalil, Salil, Fackrell, David, Hoskin, Peter, Sydes, Matthew R., Chowdhury, Simon, Gilbert, Duncan C., Parmar, Mahesh K. B., James, Nicholas D., Langley, Ruth E.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2022
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7612717/
https://ncbi.nlm.nih.gov/pubmed/34757812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.21.00728
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!